+41 91 682 20 40 info@elixi-int.com

ABOUT US

We are a Swiss pharmaceutical wholesaler, specialized in sourcing and delivering pharma products, medical devices and drugs from and to all over the world.

Here in ELIXI we consider fast delivery of life-saving medicines as a basic but mandatory human value.

 

QUALITY

As a pharmaceutical wholesaler, working directly with pharma manufactures, medicine distributors, hospitals and clinics, we comply with the newest Standard Operating Procedures (SOPs), which guide our professional team step-by-step in all of ELIXI’s activities ensuring the highest quality standards required by the pharma world.

> Read more

 

WHO WE ARE

We deliver pharma products from Switzerland and from all over the world.

Our team in ELIXI International has a solid experience in the distribution of medical products.

History has taught us to prioritize the urgency that lays behind the need of supplying a drug in the fastest possible way. Here in ELIXI we consider fast delivery as a basic but mandatory human value. In order to achieve this goal, we developed a simple but qualified process made of synergies with long lasting partners who, like us, believe in people and not in machines.

 

NEWS

Luxturna (voretigene neparvovec), first treatment option for hereditary retinal dystrophy with mutations of the RPE65 gene recommended for authorisation by EMA

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation for the gene therapy Luxturna…

read more

New monoclonal antibody Emgality ( galcanezumab) for the prevention of migraine

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation for Emgality (galcanezumab), a monoclonal…

read more

New medicine to treat infections in adults: Vabomere, a combination of an antibiotic and new beta-lactamase inhibitor, addresses bacterial resistance.

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation for Vabomere (meropenem trihydrate/vaborbactam), a…

read more

Nerlynx, neratinib, a breast cancer medicine used to reduce the risk of the disease coming back in patients with early breast cancer who have had surgery.

Nerlynx is indicated for the extended adjuvant treatment of adult patients with early stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who…

read more

FDA approves Lumoxiti (moxetumomab pasudotox-tdfk), new kind of treatment for hairy cell leukemia

The U.S. Food and Drug Administration has approved Lumoxiti (moxetumomab pasudotox-tdfk) injection for intravenous use for the treatment of adult…

read more

FDA approves first generic version of EpiPen

The U.S. Food and Drug Administration has approved the first generic version of EpiPen and EpiPen Jr (epinephrine) auto-injector for…

read more

Cablivi (caplacizumab) approved in Europe for adults with acquired thrombotic thrombocytopenic purpura (aTTP)

The European Commission has granted marketing authorization for Cablivi (caplacizumab) for the treatment of adults experiencing an episode of acquired…

read more

Vyxeos (daunorubicin and cytarabine) Receives Marketing Authorisation in the European Union for Treatment of Certain Types of High-Risk Acute Myeloid Leukaemia

Jazz Pharmaceuticals plc has announced that the European Commission approved Vyxeos 44 mg/100 mg powder for concentrate for solution for infusion for the…

read more

Duzallo (allopurinol and lesinurad), for the treatment of hyperuricaemia in gout patients who have not achieved target serum uric acid levels with an adequate dose of allopurinol alone.

Duzallo is a medicine used in adults with gout to reduce high levels of uric acid in the blood. It…

read more

FDA approves Oxervate (cenegermin) first drug for neurotrophic keratitis, a rare eye disease

The U.S. Food and Drug Administration has approved the first drug, Oxervate (cenegermin), for the treatment of neurotrophic keratitis, a…

read more

FDA approves Galafold ( migalastat), a new treatment for a rare genetic disorder, Fabry disease

The U.S. Food and Drug Administration has approved Galafold (migalastat), the first oral medication for the treatment of adults with…

read more

FDA approves Lenvima (lenvatinib) for unresectable hepatocellular carcinoma

On August 16, 2018, the Food and Drug Administration approved lenvatinib capsules (Lenvima, Eisai Inc.) for first-line treatment of patients…

read more

CONTACT US

ELIXI International SA

Piazza Boffalora 4
6830 Chiasso / Switzerland

Tel: +41 91 682 20 40

Your name (required)

Your e-mail (required)

Your message

captcha